In this study, the median proportion of BCMA expression in myeloma cells was 2.65% (range, 0.00–89.01%), the efficacy of the BCMA expression negative patient (patient 4) was SD at 28-day and one month later was PD. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.